Pfizer, AstraZeneca and several other drugmakers in race to join weight loss drug market Ruchika Sharma23 Dec 2024 5:01 PM ISTPfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated to be worth about $150...
Novo Nordisk bleeding disorder injection gets USFDA nod Ruchika Sharma21 Dec 2024 11:30 AM ISTPlainsboro: Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) has approved Alhemo (concizumab-mtci) injection as a...
Novavax to sell Bohumil manufacturing facility to Novo Nordisk for USD 200 million Ruchika Sharma4 Dec 2024 4:56 PM ISTGaithersburg: Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M adjuvant, today announced that it has signed a...
Novo Nordisk Enters China's Obesity Market with Wegovy Launch, Eyes 180 Million Patients Farhat Nasim20 Nov 2024 1:36 PM ISTThe move intensifies the competition with Eli Lilly, which secured approval for its weight loss drug in China in July but has yet to launch it.
Semaglutide 2.4 mg may significantly improve liver fibrosis and resolve MASH in ESSENCE trial Dr. Kamal Kant Kohli5 Nov 2024 9:30 AM ISTAccording to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver fibrosis and...
CDSCO Panel grants Novo Nordisk Protocol Amendment Proposal to study concizumab Dr. Divya Colin27 Oct 2024 5:00 PM ISTNew Delhi: Recommending to increase the number of subjects from 15 to 35, the Subject Expert Committee (SEC) functional under the Central Drug...
West Pharma Raises 2024 Profit Forecast Amid Surging Demand for Injectable Therapy Supplies MD Bureau27 Oct 2024 9:45 AM ISTBengaluru: West Pharmaceutical Services raised its annual profit outlook on Thursday after exceeding Wall Street's expectations for quarterly...
Roche seeks to block Novo Nordisk's Catalent deal over weight-loss drug competition MD Bureau24 Oct 2024 2:09 PM IST"Limiting the competition in this space is not a good idea," Thomas Schinecker, CEO, Roche said.
Novo Nordisk's oral Semaglutide cuts cardiovascular risks by 14 percent, study finds MD Bureau23 Oct 2024 3:29 PM ISTNovo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.
Oral semaglutide cuts MACE risk by 14% in adults with type 2 diabetes: SOUL trial Dr. Kamal Kant Kohli22 Oct 2024 9:30 AM ISTAccording to new data from the SOUL trial Oral semaglutide reduced MACE by 14% in Type 2 Diabetes patients. Novo Nordisk will present more detailed...
Block Novo Holdings' USD16.5B Catalent acquisition: Consumer Groups Urge FTC over antitrust concerns MD Bureau19 Oct 2024 11:30 AM ISTThe deal could constrain options for competitors such as Amgen, Pfizer, Roche, and AstraZeneca , who are reportedly developing their own GLP 1 drugs.
Natco Pharma partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US Ruchika Sharma7 Oct 2024 12:30 PM ISTHyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S....
